In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Traditional pathology approaches have played an integral role in the delivery of diagnosis,
semi-quantitative or qualitative assessment of protein expression, and classification of …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Background Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor
prognosis and no established therapy. Recently, encouraging responses to immune …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …

Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …